IL6 and COVID-19: With regards to Tocilizumab treatment and COVID-19, multiple centers have found that Tocilizumab treatment has been associated with improved outcomes, and that measured IL-6 tended to decrease after Tocilizumab treatment in patients with improved outcomes, while IL-6 tended to increase in those with worse outcomes (Luo et al., 2020; Xu et al., 2020).